<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">San Miguel, J.F.</style></author><author><style face="normal" font="default" size="100%">Weisel, K.C.</style></author><author><style face="normal" font="default" size="100%">Song, K.W.</style></author><author><style face="normal" font="default" size="100%">Delforge, M.</style></author><author><style face="normal" font="default" size="100%">Karlin, L.</style></author><author><style face="normal" font="default" size="100%">Goldschmidt, H.</style></author><author><style face="normal" font="default" size="100%">Moreau, P.</style></author><author><style face="normal" font="default" size="100%">Banos, A.</style></author><author><style face="normal" font="default" size="100%">Oriol, A.</style></author><author><style face="normal" font="default" size="100%">Garderet, L.</style></author><author><style face="normal" font="default" size="100%">Cavo, M.</style></author><author><style face="normal" font="default" size="100%">Ivanova, V.</style></author><author><style face="normal" font="default" size="100%">Alegre, A.</style></author><author><style face="normal" font="default" size="100%">Martinez-Lopez, J.</style></author><author><style face="normal" font="default" size="100%">Chen, C.</style></author><author><style face="normal" font="default" size="100%">Renner, C.</style></author><author><style face="normal" font="default" size="100%">Bahlis, N.J.</style></author><author><style face="normal" font="default" size="100%">Yu, X.</style></author><author><style face="normal" font="default" size="100%">Teasdale, T.</style></author><author><style face="normal" font="default" size="100%">Sternas, L.</style></author><author><style face="normal" font="default" size="100%">Jacques, C.</style></author><author><style face="normal" font="default" size="100%">Zaki, M.H.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma</style></title><secondary-title><style face="normal" font="default" size="100%">Haematologica</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943235900&amp;doi=10.3324%2fhaematol.2015.125864&amp;partnerID=40&amp;md5=884d75796ce88e5bf968461186dccbdb</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">100</style></volume><pages><style face="normal" font="default" size="100%">1334 - 1339</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Pomalidomide is a distinct oral IMiD® immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 patients with refractory or relapsed and refractory multiple myeloma after failure of bortezomib and lenalidomide treatment. Initial results demonstrated significantly longer progression-free survival and overall survival with an acceptable tolerability profile for pomalidomide + low-dose dexamethasone vs high-dose dexamethasone. This secondary analysis describes patient outcomes by treatment history and depth of response. Pomalidomide + low-dose dexamethasone significantly prolonged progression-free survival and favored overall survival vs high-dose dexamethasone for all subgroups analyzed, regardless of prior treatments or refractory status. Both univariate and multivariate analyses showed that no variable relating to either the number (≤ or &gt; 3) or type of prior treatment was a significant predictor of progression-free survival or overall survival. No cross-resistance with prior lenalidomide or thalidomide treatment was observed. Patients achieving a minimal response or better to pomalidomide + low-dose dexamethasone treatment experienced a survival benefit, which was even higher in those achieving at least a partial response (17.2 and 19.9 months, respectively, as compared with 7.5 months for patients with less than minimal response). These data suggest that pomalidomide + low-dose dexamethasone should be considered a standard of care in patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment. ClinicalTrials.gov: NCT01311687; EudraCT: 2010-019820-30. © 2015 Ferrata Storti Foundation.</style></abstract><issue><style face="normal" font="default" size="100%">10</style></issue><notes><style face="normal" font="default" size="100%">Cited By :8Export Date: 21 February 2017</style></notes></record></records></xml>